Rapid detection of 3500Q and 3531 mutations and MspI polymorphism in exon 26 at the apolipoprotein B gene
- PMID: 11170232
- PMCID: PMC6808027
- DOI: 10.1002/1098-2825(2001)15:1<35::aid-jcla7>3.0.co;2-p
Rapid detection of 3500Q and 3531 mutations and MspI polymorphism in exon 26 at the apolipoprotein B gene
Abstract
Several environmental and genetic factors are associated with high levels of cholesterol. Hypercholesterolemia is the main phenotype of Familial Defective Apolipoprotein B and Familial Hypercholesterolemia that are caused by mutations at the apolipoprotein (apo) B and LDL receptor genes, respectively. Identification of the specific genetic alteration associated with hypercholesterolemia is an important issue in clinical diagnosis of high risk for CAD. Apo B gene mutations and polymorphisms are usually screened by SSCP, DGGE, and heteroduplex, which must be confirmed by DNA sequencing or by direct detection using PCR techniques. In this study, we have optimized a PCR-RFLP procedure for identification of 3500Q and 3531 mutations and MspI polymorphism at the apo B gene. The technique can be performed in a single reaction, using the restriction endonuclease MspI for simultaneous detection of 3500Q mutation and MspI polymorphism, and NsiI for detection of 3531 mutation. The procedure was validated by analysis of control DNA samples from individuals carrying these mutations. Screening of 186 Brazilian hypercholesterolemic individuals showed that the frequency of the M-allele (7.8%) of MspI polymorphism was similar to that found in other individuals with CAD. However, neither 3500Q nor 3531 mutations were detected in this group. In conclusion, this procedure is simple and rapid, being easily introduced in clinical laboratories for direct detection of the more frequent mutations at the apo B gene associated with hypercholesterolemia.
Similar articles
-
Apolipoprotein B gene polymorphisms: prevalence and impact on serum lipid concentrations in hypercholesterolemic individuals from Brazil.Clin Chim Acta. 2000 Dec;302(1-2):189-203. doi: 10.1016/s0009-8981(00)00367-3. Clin Chim Acta. 2000. PMID: 11074075
-
The MspI restriction fragment length polymorphism 3' to the apolipoprotein A-II gene: relationships with lipids, apolipoproteins, and premature coronary artery disease.Atherosclerosis. 1992 Feb;92(2-3):165-76. doi: 10.1016/0021-9150(92)90275-l. Atherosclerosis. 1992. PMID: 1352975
-
DNA polymorphisms of the apolipoprotein B gene (XbaI, EcoRI, and MspI RFLPs) in Norwegians at risk of atherosclerosis and healthy controls.Acta Cardiol. 1999 Aug;54(4):215-25. Acta Cardiol. 1999. PMID: 10511898
-
The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.Dan Med Bull. 2002 Nov;49(4):318-45. Dan Med Bull. 2002. PMID: 12553167 Review.
-
Familial defective apolipoprotein B-100.Dan Med Bull. 1998 Sep;45(4):370-82. Dan Med Bull. 1998. PMID: 9777289 Review.
References
-
- Galton DJ. 1997. Genetic determinants of atherosclerosis‐related dyslipidemias and their clinical implications. Clin Chem Acta 257:181–197. - PubMed
-
- Stepanov VA, Puzyrev VP, Karpov RS, Kutmin AI. 1998. Genetic markers in coronary artery disease in a Russian population. Hum Biol 70:47–57. - PubMed
-
- Salazar LA, Hirata MH, Forti N, et al. 2000. PvuII intron 15 polymorphism at the LDL receptor gene is associated with differences in serum lipid concentrations in subjects with low and high risk for coronary artery disease from Brazil. Clin Chim Acta 293:75–88. - PubMed
-
- Salazar LA, Giannini SD, Forti N, et al. 1999. Polymorphisms of the candidate genes of atherosclerosis in Brazilian women with coronary artery disease. Atherosclerosis 144(1):185. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous